Cassiopea (CPPSF) Stock Price, News & Analysis

Company Overview

Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. It offers Winlevi, an antiandrogen, which has completed Phase III clinical trial for the topical treatment of acne; Breezula, a topical antiandrogen that is in Phase II clinical trial to treat androgenic alopecia; CB-06-01, a topical antibiotic, which is in Phase II clinical trial for the treatment of acne, including strains resistant to other antibiotics; and CB-06-02, a novel integrin activator that has completed Phase II clinical trial to treat genital warts. The company was formerly known as Cosmo Dermatos S.r.l. Cassiopea S.p.A. was founded in 2013 and is based in Lainate, Italy. As of December 2, 2021, Cassiopea S.p.A. operates as a subsidiary of Cosmo Pharmaceuticals N.V.

Key Stats

• Today's Range: $35.15 to $35.15
• 50-Day Range: $35.15 to $35.15
• 52-Week Range: $35.15 to $55.81
• Volume: N/A
• Average Volume: 608 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CPPSF Stock Analysis - Frequently Asked Questions

How have CPPSF shares performed this year?

Cassiopea's stock was trading at $35.15 at the beginning of 2025. Since then, CPPSF stock has increased by 0.0% and is now trading at $35.15.
View the best growth stocks for 2025 here.

How do I buy shares of Cassiopea?

Shares of CPPSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CPPSF
• CIK: N/A
• Web: www.cassiopea.com
• Phone: (928) 689-1124
• Fax: N/A
• Employees: 11
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A